Neoplasms Metastasis, HER2, Survival Analysis, Pertuzumab, Cohort Study
Neoplasms metastasis, HER2, Survival Analysis, pertuzumab, Cohort Study
Ovarian function suppression, HER2 positive, adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, LHRH agonists, neoadjuvant, residual disease, pathological complete response
breast neoplasms, neoplasm metastasis, biopsy, Receptor, Estrogen, Receptor, Progesterone, Receptor, ErbB-2